PuO 2 and 238 PuO 2 have been determined based on available biokinetic data from studies in rodents, and the impacts of these parameters on bioassay interpretation and dosimetry after inhalation of nanoPuO 2 materials have been evaluated. Calculations of activities after an acute intake of nanoparticles of 239 PuO 2 and 238 PuO 2 are compared with the corresponding calculations using standard default absorption parameters using the International Commission on Radiological Protection (ICRP) 66 respiratory tract model. Committed effective doses are also evaluated and compared. In this case, it was found that interpretation of bioassay measurements with the assumption that the biokinetic behaviour of PuO 2 nanoparticles is the same as that of micrometre-sized particles can result in an overprediction of the committed effective dose by two orders of magnitude. Although in this case the use of the default assumptions (5 mm AMAD, Type S) for assessing dose following inhalation exposure to airborne PuO 2 nanoparticles appears to be conservative, the evaluation of situations involving PuO 2 nanoparticles that may have different particle size and solubility properties should prudently follow the ICRP recommendation to obtain and use additional, material-specific information whenever possible.
INTRODUCTION
Default blood absorption parameters for radionuclides in the lungs are described and discussed in International Commission on Radiological Protection (ICRP) Publication 66 on the Human Respiratory Tract Model (HRTM) (1) . However, as pointed out in ICRP Publication 30, if the behaviour of any specific material is expected to differ significantly from that of the biokinetic model employed, then the model parameters should be modified to take account of the available data (2) . In the case of plutonium (Pu), a considerable number of studies involving Pu particles in the micrometre size range have demonstrated that in general plutonium dioxides (PuO 2 ) behave as a Type S material (3) . It is of interest to determine how the use of materialspecific particle size and bioassay parameters for PuO 2 materials in the nanosize range might influence decision-making for health protection.
Traditional risk management of the biological effects and related health consequences of inhalation exposure to radionuclides such as PuO 2 has relied on data and default assumptions from studies involving particles in the micrometre size range. Nonetheless, as work with nanometre-sized materials expands, it is reasonable to ask whether the biological behaviour of plutonium dioxide in the nanometre size range might differ significantly from its behaviour in the micrometre size range. While the current default values for biokinetic models are representative of the experience base for materials in the micrometre size range, there has been no assessment to date as to whether or not the use of the defaults would be protective for someone exposed to 239 PuO 2 and 238 PuO 2 in the nanosize range. Correct assessment of the biokinetic behaviour of Pu following an inhalation exposure requires determination of when default assumptions are adequate or when material-specific information is needed.
The impacts using specific absorption parameters for 239 PuO 2 and 238 PuO 2 and the impacts on bioassay interpretation and dosimetry after inhalation of nanoPuO 2 materials need to be evaluated. To address this, historical data on the biokinetic behaviour of Pu observed in rats, exposed by pulmonary intubation to plutonium dioxide (PuO 2 ) nanoparticles, are used to derive specific blood absorption parameters for use with the HRTM published by the ICRP, ICRP Publication 66. This work illustrates the use of material-specific particle size and bioassay parameters with corresponding bioassay tables and dose coefficients. Calculations of activities after an acute intake of nanoparticles of are compared with the corresponding calculations using standard default absorption parameters using the ICRP 66 respiratory tract model. Committed effective doses are also evaluated and compared.
MATERIALS AND METHODS

Available data
There are no human data available to assess absorption of PuO 2 from nanometre-sized particles in the respiratory tract. Therefore, biokinetic information must be derived from experiments with laboratory animals, notably the studies conducted by Smith et Pu particles that were produced by arc vaporisation of a Pu metal wire were obtained by membrane filtration into sizes ,25 nm, 25-220 nm and 220 nm to 1.2 mm physical diameters. Separation of particles in the ,25 nm suspension via membrane filtration with nominal pore diameters of 12, 9, 6 and 4 nm were attempted but were not successful (4) . However, ultrafiltration through a membrane with a nominal pore size of 1 nm was successful, indicating that the particle size in the ,25 nm suspension was primarily uniform with a diameter of 1 nm (4) . Particles in the largest size range (220 nm to 1.2 mm) were not used in the Smith et al. pulmonary intubation study. Stradling et al., using the same filtration method used in Smith et al., prepared size-fractionated 238 Pu particles of fresh and aged (32 weeks) particles into four particle size ranges ,25 nm, 25-220 nm and 220 nm to 1.2 mm, and 1.2-5 mm diameters. Stradling et al. attempted to fractionate the particle sizes in the ,25 nm suspension and found through electron microscopy and ultrafiltration that the ,25 nm suspension of Rats in both studies were administered the suspensions of PuO 2 nanoparticles by pulmonary intubation through a cannula temporarily inserted into the trachea. Following exposure, animals were immediately put into metabolism cages to allow for the separate collection of urine and faeces and were given access to food and water at all times. After exposure, the groups of animals exposed to 239 PuO 2 were sacrificed at 18 h, 6 d and 17 d, while the groups of animals exposed to 238 PuO 2 fresh and aged suspensions were sacrificed at 1, 6 and 21 d (4, 5) . For both studies, there were four animals in each group except for a group of eight animals that were sacrificed on (4, 5) . Smith et al. reported a uniform physical size of 1 nm for particles ,25 nm and a mass median diameter of 48 nm for material in the 25-220 nm size range. Stradling et al. also reported a uniform 1 nm particle diameter for particles ,25 nm. Conversion of physical diameters to an equivalent aerodynamic diameter was done using the equations in Section D.4.1 in Annexe D of ICRP Publication 66 (1) . For the calculation, the density of plutonium was assumed to be 9 g cm 23 and the shape factor was assumed to be 1. The aerodynamic diameters of plutonium nanoparticles were calculated to be 9 and 258 nm for 1 and 48 nm diameter particles, respectively. Thus, for the purposes of calculating daily urinary excretion and dose, nominal particle sizes were taken to be 1 and 48 nm when expressed in terms of activity median thermodynamic diameter (AMTD) and 10 and 250 nm when expressed in terms of activity median aerodynamic diameter (AMAD). For the purposes of presenting data in this paper in a uniform way across the wide particle size range from 5 um AMAD (the default workplace diameter) to 1 nm physical diameter, the authors have chosen to present graphical and tabular results in terms of AMAD. Many workplace studies involving cascade impaction provide particle size distributions in terms of aerodynamic diameter. It is appropriate to express particle sizes for nanoparticles in terms of AMTD, and some data based on diffusion analysers are available for some workplace situations. However, AMAD correspondences will be used throughout this paper for purposes of comparison of calculation results.
Determination of material-specific blood absorption parameters
Lung and systemic biokinetic models for the rat, shown in Figure 1 , were developed to fit the available experimental data. The systemic portion of the model was based on the current ICRP plutonium systemic model for humans (6) . Recycling of plutonium in organs to and from blood has also been taken into account. The model contains blood, liver1 (which describes biliary excretion), liver2 (which describes recycling back to blood and biliary excretion), carcase and other (other soft tissues). The main difference from the ICRP plutonium systemic model and the rat model developed here is that only prompt urinary excretion to the urinary bladder was considered without considering retention in the kidney compartment because the amount of available data was insufficient to support the inclusion of this pathway. To distinguish it from data in other soft tissues, a separate 'carcase' compartment was generated, which encompasses skeletal Pu content as well as that in attached undissected muscle tissue.
Transfer rates for the systemic portion of the model were derived from the intravenous injection experiments conducted by Smith et al. (4) . Transfer rates derived for 239 Pu can be seen in Table 1, and   238 Pu results are shown in Table 2 . In this work, two lung compartments, named Lung1 and Lung2, were added to the systemic model to represent the transfer processes from particles in initial state to blood (sp) and to particles in transformed state (spt) and from particles in transformed state to blood (st). Regarding the transfer rates presented in Table 1 , at first glance one would expect a greater transfer of materials from smaller particles due to their higher surface area when compared with larger particles that have a smaller surface-to-mass ratio. However, there are several pathways involved in this recycling model, so the fitting process involves the overall examination of transfer as a whole and not by individual transfer rates. In addition, it is recognised that the same metabolism can be described by different combinations of transfer rates. RATDOSE software was used to determine the material-specific blood absorption parameters (7) . It is a software application that was developed to provide the ability to empirically model the biokinetics of radionuclides administered in animal experiments. The software allows the user to produce a computational framework in which complex compartmental models together with tissue and excreta activity data can be fitted with fidelity thus minimising the uncertainties in the predictions. It has a robust statistical treatment of the data and good presentation of the results. Goodness of fit for how well the model describes the available data is assessed through the determination of x 2 .
Activities and dose calculations
Activities predicted in organs and excreta for standard workers following acute inhalation of PuO 2 for both isotopes Pu were evaluated using a software package (AIDE) that calculates activities in compartments and committed doses due to intakes of radionuclides (8) . In this work, inhalation intakes of plutonium were calculated using the ICRP HRTM (1) together with the ICRP Publication 67 plutonium systemic model (6) . Pu are also shown in Table 3 , with corresponding x 2 per degree of freedom of 6.3 for fresh and 8.4 for aged materials, which are not as good as the one obtained for 10 nm AMAD particles of 239 Pu. For larger particles of 250 nm AMAD, the corresponding x 2 per degree of freedom was 29.7 as also shown in Table 3 . While unsatisfactory in terms of the x 2 result, it is probably enough to show that larger particles present much longer lung retention as can be seen by the s t value of 1.2`Â 10 25 d
21
, which corresponds to a biological half-life of roughly 158 y. It must be noted though that this number was derived using data points for times only up to 17 d. The results for the larger particle sizes should therefore be interpreted with caution.
The derived blood absorption parameters for 239 Pu shown in Table 3 for particles of 10 nm AMAD are similar to those presented by Davesne et al. (9) who followed the recommendations of the ICRP Supporting Guidance 3 (10) for using the systemic model for plutonium in the rat when obtaining material-specific blood absorption parameters. In Supporting Guidance 3, a much simpler model is proposed in which activity (10) . The blood absorption parameters were calculated using the same data, but the results from Davesne et al. (9) were presented using the alternate representation for the blood absorption process through f r , s r and s s parameters. Comparison of the s p , s pt and s t results calculated in this work with those converted from Davesne et al. values (9) , using the relationship conversion s r ¼ s p þ s pt , f r ¼ (s p 2 s t ) / (s p þ s pt 2 s t ) and s s ¼ s t and are shown in the last column of Table 3 . The results for 239 PuO 2 are remarkably similar, despite the use of completely different methods. The results for 238 PuO 2 appear different, mainly with an order of magnitude slower removal rate (s p ) from the initial state to blood and higher retention shown for particles being absorbed from the transformed state to blood (s t ).
Using AIDE software (8) for comparison, Figure 2 shows the calculated daily urine excretion as a fraction of inhaled activity for 239 Pu for AMADs 5 mm Types M and S and AMADs of 250 and 10 nm using the calculated specific blood absorption parameters. The figure shows that fraction of activity excreted in urine for the specific materials is larger than that for the default Type S material. As expected, the urinary excretion associated with a larger particle size AMAD 250 nm appears closer to the behaviour of a more soluble Type M material. The corresponding daily urine excretion as a fraction of inhaled activity was also calculated for 238 Pu with the same magnitude difference as found for 239 Pu. Committed effective dose coefficients (e50) (Sv.Bq
) and committed equivalent dose coefficients for body organs were calculated for acute intakes of plutonium dioxide for several particle sizes and solubilities. The committed effective dose coefficients and the committed equivalent dose coefficients for bone surface and for extrathoracic region (ET) are shown in Table 4 . In most cases, the highest committed equivalent dose occurs for bone surface. The committed effective dose for inhalation intakes of 239 Pu compounds associated with nanoparticles of AMAD 10 nm is 34 times higher than that for Type S compounds with AMAD 5 mm, as seen in Table 4 .
At first glance, the significant difference in the committed effective dose coefficient could impact the setting of operational radiation exposure limits in the field since the same activity measured in a filter will be associated with a higher dose when treated as a nanoparticle material. However, when a dose assessment is performed through urine bioassay measurements, a smaller committed effective dose per unit of 239 Pu activity measured in a daily urinary excretion sample will be calculated for nanoparticles when compared with Type S materials, as shown in Figure 3 . It can be seen that the dose per unit content curves as a function of time after intake for 5 mm Types M and for nanoparticles of AMAD 10 and 250 nm using specific absorption parameters are similar and show smaller values than those for Type S compounds. The reason is because even having committed effective dose coefficients for inhalation of nanoparticles higher than that for Type S material, when it is divided by the much higher daily urinary excreted activity values for nanoparticles it results in smaller values for the ratios. It must be pointed out that the concept of dose per unit urinary excretion content is very useful for explaining the differences in committed effective dose coefficients for the several types of material when the intake estimates are made through urinalysis. However, committed dose estimates due to intakes of radionuclides using in vivo or in vitro techniques are mostly done in practice by initially performing the intake amount estimate and then using committed effective dose coefficients per unit intake to calculate the committed doses. Figure 4 shows the comparison among the committed effective dose coefficients (e50) per unit measured activity in daily urinary excretion (Sv Bq
) for acute intakes of 239 Pu for the environmentally relevant AMADs 1 mm Types F, M and S with the AMADs 250 and 10 nm using specific blood absorption parameters derived from rat pulmonary intubation studies. The 1 mm Type F and AMAD 10 nm specific curves overlap. For the material evaluated in this study, it was concluded that in the absence of bioassay data tables, which were derived using material-specific absorption parameters, practitioners could use AMAD 1 mm Type F tables to reasonably interpret results for PuO 2 particles in the AMAD 10 nm diameter size range. Based on data for the larger nanoparticles evaluated in this study, a more reasonable interpretation of bioassay Pu using the default 5 mm AMAD with Type M and S blood absorption parameters and using the AMAD 250 nm and AMAD 10 nm with corresponding material-specific blood absorption parameters. measurements can be achieved by using intake retention fraction tables derived for materials with a greater degree of solubility than the default Type S materials and a smaller particle size.
Nevertheless, studies with other materials are needed to determine if these observations are generally applicable.
CONCLUSIONS
Material-specific blood absorption parameters have been derived for PuO 2 in the nanometre size range from pulmonary intubation experiments in rats (11) . Using ICRP HRTM default parameters in the micrometre size range for PuO 2 to predict biokinetic behaviour of PuO 2 following inhalation of Pu nanoparticles of AMAD 10 and 250 nm would underpredict the urinary excretion of plutonium. For 239 Pu and 238 Pu material of AMAD 10 nm and 239 Pu of AMAD 250 nm, a higher urinary excretion of plutonium is likely to occur compared with excretion associated with Type S material of the default occupationally relevant particle size of 5 mm. The daily urinary excretion activity values for nanoparticles with an AMAD of 10 nm are about two orders of magnitude higher than those for a typical 5 mm Type S material. These conclusions assume that the biokinetic behaviours noted in the previously described rat studies are predictive of biokinetics in humans exposed to similarly produced Pu aerosols and having similar particle size distributions.
Interpretation of bioassay measurements from individuals exposed to PuO 2 nanoparticles with the assumption that the biokinetic behaviour of PuO 2 nanoparticles is the same as that of micrometre-sized Pu particle parameters can result in an overprediction of the committed effective dose by two orders of Pu using the default 5 mm AMAD Type M and S and blood absorption parameters and using the AMAD 250 nm and AMAD 10 nm materialspecific blood absorption parameters. magnitude. Consequently, intakes and committed effective doses could be overestimated from bioassay measurements if the materials contained in the exposure were known to be in the nanoparticle size range and Type S absorption parameters were assumed. The committed effective dose for inhalation intakes of 239 Pu materials associated with nanoparticles is higher than that for Type S materials with AMAD 5 mm if air measurements are used for interpretation. However, a smaller committed effective dose will be calculated when the dose assessment is performed based on urinary excretion measurements. Although in this case the use of the default assumptions (5 mm AMAD, Type S) for assessing dose following inhalation exposure to airborne PuO2 nanoparticles appears to be conservative, the evaluation of situations involving PuO 2 nanoparticles that may have different particle size and solubility properties should prudently follow the ICRP recommendation to obtain and use additional, material-specific information whenever possible.
Additional biokinetic studies of AMADs between 10 and 250 nm would be helpful to determine the size at which the transition from Type S to a more soluble behaviour occurs. Such information would provide a stronger basis for determining when the HRTM default assumptions are adequate and when materialspecific information is needed to correctly assess biokinetic behaviour associated with an inhalation exposure.
Analyses in the current work show that use of those default parameters to predict biokinetic behaviour of Pu following inhalation of PuO 2 nanoparticles can result in an underprediction of the urinary excretion of plutonium. Thus, continuing the current practice of using the traditional default assumptions for assessing dose following inhalation exposure to airborne PuO 2 nanoparticles appears to be conservative, and therefore can be justified as prudent in the absence of additional, material-specific information. 
